Perampanel

What is Perampanel?

Perampanel is an oral medication classified as an antiepileptic drug (AED), also widely known by its brand name, Fycompa. It is primarily used in the management of epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures. Unlike many older AEDs, Perampanel represents a newer class of anticonvulsants with a distinct mechanism of action, offering a valuable treatment option for patients who may not have responded adequately to other therapies.

This medication is available in tablet form and as an oral suspension, making it adaptable for various patient needs. Its introduction has provided clinicians with an additional tool to help achieve better seizure control and improve the quality of life for individuals living with epilepsy. Perampanel is specifically designed to target certain brain receptors, thereby reducing the excessive electrical activity that leads to seizures.

How Does it Work?

The mechanism of action of Perampanel is unique among currently available antiepileptic drugs. It functions as a selective, non-competitive AMPA receptor antagonist. AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are a major subtype of ionotropic glutamate receptors in the brain, playing a crucial role in excitatory neurotransmission. When these receptors are overstimulated, it can lead to neuronal hyperexcitability, a hallmark of seizure activity.

By selectively blocking the AMPA receptors, Perampanel reduces the excessive excitatory signaling in the brain that contributes to seizure generation and propagation. This non-competitive antagonism means it binds to a site on the receptor different from where glutamate binds, effectively modulating the receptor's activity without directly competing with the natural neurotransmitter. This novel approach helps to stabilize neuronal membranes and prevent the uncontrolled electrical discharges that manifest as seizures, offering a distinct pathway to antiepileptic efficacy.

Medical Uses

Perampanel is approved for the treatment of various types of seizures in patients with epilepsy. Its primary indications include:

• Adjunctive Treatment of Partial-Onset Seizures:

  Perampanel is indicated as an add-on therapy for the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy aged 4 years and older. Partial-onset seizures originate in one area of the brain and can sometimes spread to cause a generalized seizure.

• Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures:

  It is also approved as an add-on therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. These seizures affect both sides of the brain from the outset and involve stiffening of the body (tonic phase) followed by rhythmic jerking (clonic phase).

In some regions, Perampanel has also gained approval as monotherapy (used alone) for the treatment of partial-onset seizures in certain adult and adolescent populations, further expanding its utility.

Dosage

The dosage of Perampanel must be individualized based on the patient's response and tolerability, and it is typically titrated slowly to reach an effective maintenance dose. It is administered orally, once daily, usually at bedtime, with or without food.

• Initial Dose: The usual starting dose for adults and adolescents (12 years and older) is 2 mg once daily.
• Titration: The dose is gradually increased, typically by 2 mg increments, at weekly or bi-weekly intervals, based on clinical response and tolerability.
• Maintenance Dose: The recommended maintenance dose for partial-onset seizures is generally 4 mg to 12 mg once daily. For primary generalized tonic-clonic seizures, the recommended maintenance dose is usually 8 mg once daily.

Specific dosage adjustments may be necessary for patients with hepatic impairment, as well as when co-administered with certain medications that affect Perampanel metabolism. Pediatric dosing (for children 4 years and older) follows similar titration principles but may involve different initial and maintenance dose ranges based on weight and age, always under the guidance of a healthcare professional.

Side Effects

Like all medications, Perampanel can cause side effects, although not everyone experiences them. It is crucial to discuss any concerns with your doctor.

Common Side Effects:

• Dizziness
• Somnolence (drowsiness)
• Fatigue
• Headache
• Nausea
• Irritability
• Ataxia (impaired coordination)
• Weight gain
• Vertigo

Serious Side Effects:

Some side effects, though less common, can be serious and require immediate medical attention. These include:

• Neuropsychiatric Events: Perampanel has been associated with severe behavioral changes, including aggression, hostility, anger, agitation, and suicidal thoughts or behavior. Patients and caregivers should monitor for new or worsening mood changes.
• Severe Allergic Reactions: Though rare, severe skin reactions (e.g., Drug Reaction with Eosinophilia and Systemic Symptoms - DRESS) can occur.
• Increased Risk of Falls: Due to dizziness and ataxia.

Patients should be advised not to drive or operate heavy machinery until they know how Perampanel affects them, especially during the initial titration phase.

Drug Interactions

Perampanel can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects. It is essential to inform your doctor about all prescription, over-the-counter, and herbal supplements you are taking.

• Enzyme-Inducing Antiepileptic Drugs (AEDs):

  Strong CYP3A4 inducers, such as carbamazepine, phenytoin, and oxcarbazepine, can significantly decrease Perampanel plasma concentrations, potentially reducing its efficacy. Dosage adjustments of Perampanel may be necessary when co-administered with these drugs.

• Other CYP3A4 Inducers:

  Rifampin and St. John's Wort can also induce CYP3A4 and similarly reduce Perampanel levels.

• Oral Contraceptives:

  Perampanel, especially at higher doses (e.g., 12 mg/day), can decrease the effectiveness of progestin-only oral contraceptives. Women using hormonal contraception should consider alternative or additional non-hormonal birth control methods.

• Alcohol and CNS Depressants:

  Concomitant use of Perampanel with alcohol or other central nervous system (CNS) depressants can exacerbate CNS depressant effects, such as drowsiness, dizziness, and impaired coordination.

Always consult your healthcare provider before starting or stopping any medication while on Perampanel.

FAQ

Q: Is Perampanel a controlled substance?

A: While Perampanel is not classified as a controlled substance in all countries, it does have a potential for abuse and dependence, and withdrawal symptoms can occur if discontinued abruptly. Healthcare providers should assess patients for a history of drug abuse prior to prescribing.

Q: How quickly does Perampanel start working?

A: Perampanel's effects are typically seen gradually as the dose is slowly titrated upwards. It is not designed for immediate seizure cessation but rather for long-term seizure control. Patients usually start at a low dose and increase it over several weeks.

Q: Can I stop Perampanel suddenly?

A: No, abruptly stopping Perampanel can increase the risk of rebound seizures or worsening of existing seizures. It should always be tapered down gradually under the supervision of a healthcare professional.

Q: Is Perampanel safe during pregnancy?

A: Perampanel is generally considered pregnancy category C, meaning animal studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant humans. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Pregnant women or those planning pregnancy should discuss this with their doctor.

Products containing Perampanel are available through trusted online pharmacies. You can browse Perampanel-based medications at ShipperVIP or Medicenter.

Summary

Perampanel stands as a significant advancement in the treatment of epilepsy, offering a unique mechanism of action as a selective, non-competitive AMPA receptor antagonist. It is an effective antiepileptic drug for the adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures, and in some cases, as monotherapy for partial-onset seizures. Its ability to modulate excitatory neurotransmission provides a valuable option for patients seeking improved seizure control.

While generally well-tolerated, awareness of potential side effects, especially neuropsychiatric events, and important drug interactions is crucial. Successful treatment with Perampanel relies on careful dosage titration, close monitoring by a healthcare professional, and open communication regarding any concerns. Patients should never adjust their dosage or discontinue the medication without medical guidance, ensuring optimal safety and efficacy in managing their epilepsy.